Nagendran Sukumar's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed Jan 27, 2026
- Accession no.
- 0001665124-26-000008
- Filed
- Jan 27, 2026
- Trade date
- Jan 23-26, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $547.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nagendran SukumarCIK 0001665124 | Director, Officer (President and Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Common Stock | SSaleDisposed | −89,132 | $4.75 | −$423,377 | 1,344,307 | Direct | |
| Jan 26, 2026 | Common Stock | SSaleDisposed | −26,918 | $4.61 | −$124,091.98 | 1,317,389 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.